KPA to press Roche Korea over returned stock issue.

Published: 2005-04-21 06:57:00

Updated: 2005-04-21 06:57:00

Roche Korea has emerged as one of the uncooperative companies to the Korea Pharmaceutical Association over the returned stock issue, and therefore the KPA is strongly giving a pressure to Roche.

The KPA filed an administrative measure to the KFDA for Caldivita chewable tablets and Madopar tab...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK